share_log

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

股票中心的肥胖症藥物相關股票週三下跌 - 艾禮禮、諾和諾德、維京治療、結構治療發生了什麼?
Benzinga ·  07/17 22:47

Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.

禮來(紐交所:LLY)、Novo Nordisk A/S(紐交所:NVO)、viking therapeutics股票(NASDAQ:VKTX)和Structure Therapeutics Inc(納斯達克:GPCR)週三交易走低。

What happened? Earlier on Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity.

發生了什麼事?週三早些時候,瑞士羅氏控股AG(場外交易:RHHBY)宣佈Ct-996用於2型糖尿病和肥胖症的正在進行的多項1期臨床試驗的兩個分支的頭部結果。

The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.

數據顯示,Ct-996在沒有2型糖尿病的肥胖病人中治療4周後,平均體重損失較安慰劑組減少了6.1%,屬於臨床意義上的。

This data is better compared to existing competitors.

相比現有競爭對手,這組數據更好。

Also Read: EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO.

此外閱讀:獨家:Tema etf CEO預測GLP-1減重藥有望成爲萬億市場。

In March, Viking Therapeutics released results from the company's Phase 1 multiple ascending dose trial of an oral tablet formulation of VK2735 in development for metabolic disorders such as obesity.

3月,viking therapeutics發佈了公司VK2735口服片劑的1期多劑量升級試驗的結果,用於代謝性疾病,如肥胖症。

Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline of up to 5.3%, and relative to placebo, ranging up to 3.3%.

接受VK2735的隊伍顯示出依賴劑量的平均體重降低,相對於安慰劑減輕了高達5.3%,相對於安慰劑減輕了高達3.3%。

In a study published on the JAMA Internal Medicine website, Eli Lilly's Mounjaro users experienced a mean loss in body weight of 5.9% at three months, compared to 3.6% for Novo Nordisk's Ozempic users.

在《JAMA Internal Medicine》網站上發表的一項研究中,Eli Lilly的Mounjaro用戶在三個月內平均體重減輕了5.9%,而Novo Nordisk的Ozempic用戶減輕了3.6%。

At six months, the mean loss was 10.1% for Mounjaro users versus 5.8% for Ozempic users. At 12 months, the mean body weight loss for Mounjaro users was 15.3% and 8.3% for Ozempic users.

在六個月內,Mounjaro用戶的平均減重爲10.1%,而Ozempic用戶的平均減重爲5.8%。在12個月內,Mounjaro用戶的平均減輕體重爲15.3%,Ozempic用戶爲8.3%。

In June, Structure Therapeutics Inc. (NASDAQ:GPCR) unveiled 12-week topline obesity data from its Phase 2a study of GSBR-1290, demonstrating a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks.

6月,Structure Therapeutics Inc.(納斯達克:GPCR)發佈了其GSBR-1290第2a期研究的12周頭部肥胖數據,表明在12周內體重平均減輕了6.2%,具有臨床意義和統計學顯著的安慰劑調整平均數。

At Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss, and 33% achieved ≥ 10% weight loss, compared to 0% for placebo.

在第12周,GSBR-1290組中有67%的參與者達到≥6%體重減輕目標,33%的人達到了≥10%的體重減輕目標,而安慰劑組爲0%。

Price Action: At last check Wednesday, LLY stock was down 3.00% at $913.37, NVO shares were down 4.15% at $135.02, GPCR stock was down 16.01% at $37.50, and VKTX shares were down 11.10% at $50.70.

股價行情:最新檢查週三,LLY股票下跌3.00%至913.37美元,NVO股票下跌4.15%至135.02美元,GPCR股票下跌16.01%至37.50美元,VKTX股票下跌11.10%至50.70美元。

  • Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient.
  • 一項研究顯示,僅有25%的患者在使用諾和諾德的Wegovy或Ozempic 2年後仍堅持使用;公司稱數據不足。

Photo by Vidmir Rais via Pixabay

來自Pixabay的Vidmir Rais攝影作品

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論